Skip to main content

Umeclidinium / Vilanterol Dosage

Medically reviewed by Last updated on Jul 15, 2022.

Applies to the following strengths: 62.5 mcg-25 mcg/inh

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

One inhalation (umeclidinium 62.5 mcg-vilanterol 25 mcg) orally once a day
Maximum dose: One inhalation every 24 hours

Use: Long term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.



  • Severe hypersensitivity to milk proteins
  • Hypersensitivity to any of the ingredients
  • Use of a long-acting Beta2 (LABA) agonist without an inhaled corticosteroid (ICS) in asthma patients
  • This drug is not indicated for asthma treatment.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

  • This drug should be taken at the same time every day.
  • This drug should be used by orally inhaled route only.
  • Discard 6 weeks after opening the foil tray or when the counter reads zero, whichever comes first.

Storage requirements:
  • Store in the unopened protective foil tray in a dry place away from direct heat or sunlight, and only open when ready to use.

Reconstitution/preparation techniques: The manufacturer's product information should be consulted.

  • This drug should not be used to relieve acute symptoms of COPD.
  • For the treatment of acute symptoms use a rescue inhaler (i.e., albuterol).

Patient advice:
  • Patients should seek medical attention immediately if their COPD symptoms get worse, if they need more inhalations than usual of their rescue inhaler, if they develop signs and symptoms of narrow-angle glaucoma and/or urinary retention.
  • Patients should not stop therapy with this drug without physician/provider guidance since symptoms may recur after discontinuation.
  • Patients should not use other medicines containing a long-acting beta2 agonists (LABA).
  • Patients should not use more than the recommended once daily dose of this drug.
  • If short-acting beta2 agonists have been taken on a regular basis, discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms.
  • Patients should report immediately any signs or symptoms of palpitations, chest pain, rapid heart rate, tremor, or nervousness.
  • Discontinue this drug if paradoxical bronchospasm occurs.
  • Write the date you open the tray on the label on the inhaler.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.